OBIZUR is a recombinant DNA-derived, antihemophilic factor (Porcine Sequence) indicated for the treatment of bleeding episodes in adults with acquired hemophilia A, a rare and potentially life-threatening condition where the body's immune system attacks factors necessary for blood clotting. Unlike congenital hemophilia, which is inherited, acquired hemophilia A occurs in individuals with no family history of the disorder. OBIZUR provides a temporary replacement for the deficient clotting factor VIII, specifically tailored to bypass the patient's immune response against human factor VIII. This innovative approach allows for effective management of bleeding episodes, offering a critical therapeutic option for those affected by this rare autoimmune disorder.